Par Pharmaceutical, Inc.

Hoffmann-La Roche Inc.

Plexxikon Inc.

Nastech Pharmaceutical Company, Inc.

Qol Medical LLC

F. Hoffmann-La Roche Ag

Zenaida Go

Steven C Quay

Anthony P Sileno

Peter C Aprile

Jorge C De Meireles

Arati Deshpande

Prabha N Ibrahim

Navnit Hargovindas Shah

Dipen Desai

Harpreet Kaur Sandhu

Gary Conard Visor

Hans-Juergen Mair

Ralph Diodone

Nicole Wyttenbach

Stephan Lauper

Johannes Pudewell

Frank Wierschem

Raman Iyer

Harpreet K Sandhu

Antonio A Albano

James DiNunzio

Raman Mahadevan Iyer

James Dinunzio

Mahadevan Iyer Raman

Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide.

Compositions and uses thereof

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum&#xd7;100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be used to treat osteoporosis, Paget's bone disease and hypercalcemia.

Nasal calcitonin formulations containing chlorobutanol

Compositions suitable for intranasal administration containing calcitonin, chlorobutanol, a pH of about 3.5, and sodium chloride, and an intranasal spray and a pharmaceutical delivery device thereof.

Growing community of inventors

Clifton, NJ, United States of America

Zenaida Go